Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 439
- Registration Number
- NCT03139604
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸Advocate Lutheran General Hospital - Oncology Specialists SC, Park Ridge, Illinois, United States
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03132324
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Acevedo Clinical Research Associates, Miami, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 126
- Registration Number
- NCT03126019
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
🇺🇸Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03123588
- Locations
- 🇺🇸
Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York, United States
🇺🇸Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
🇺🇸Tift Regional, Tifton, Georgia, United States
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT03112603
- Locations
- 🇵🇷
Incyte Investigative Site, Ponce, Puerto Rico
🇬🇧Novartis Investigative Site, Manchester, United Kingdom
🇷🇴Novartis Investigational Site, Bucharest, Romania
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 157
- Registration Number
- NCT03099304
- Locations
- 🇺🇸
NORTHWESTERN UNIVERSITY, 676 N Saint Clair, Chicago, Illinois, United States
🇺🇸WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY, 969 N. Mason Road, Saint Louis, Missouri, United States
🇺🇸CENTRAL SOONER RESEARCH, 900 N Porter Ave, Norman, Oklahoma, United States
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT03085914
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 325
- Registration Number
- NCT03059823
- Locations
- 🇵🇱
Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland
🇵🇱Medical University of Warsaw - 2Nd Department Obstetric and Gynecology, Warsaw, Poland
🇵🇱Centrum Onkologii - Instytut Im. Marii Sklodowskiej - Curie, Warsaw, Poland
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03039114
- Locations
- 🇮🇹
UO Ematologia ASST Spedali Civili, Brescia, Italy
🇺🇸Clinical Research Alliance, Lake Success, New York, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT03011372
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇫🇷Chu de Nice - Hospital L Archet, Nice Cedex 3, France
🇩🇪Universitatsklinikum Jena, Jena, Germany